Eversept Partners LP Purchases New Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Eversept Partners LP purchased a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) during the 4th quarter, HoldingsChannel reports. The firm purchased 220,196 shares of the company’s stock, valued at approximately $1,691,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in iTeos Therapeutics during the 3rd quarter worth $102,000. Clear Harbor Asset Management LLC bought a new position in iTeos Therapeutics in the 4th quarter worth approximately $96,000. SG Americas Securities LLC lifted its holdings in shares of iTeos Therapeutics by 12.2% during the fourth quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock worth $106,000 after buying an additional 1,508 shares during the last quarter. Marquette Asset Management LLC bought a new stake in shares of iTeos Therapeutics in the fourth quarter valued at approximately $122,000. Finally, Wells Fargo & Company MN increased its position in iTeos Therapeutics by 16.9% during the fourth quarter. Wells Fargo & Company MN now owns 16,644 shares of the company’s stock worth $128,000 after acquiring an additional 2,402 shares during the period. Institutional investors and hedge funds own 97.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ITOS shares. HC Wainwright reissued a “buy” rating and set a $46.00 target price on shares of iTeos Therapeutics in a research report on Thursday, March 6th. Wells Fargo & Company cut their price target on shares of iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th. Wedbush restated an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. dropped their price objective on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th.

iTeos Therapeutics Stock Up 1.7 %

Shares of ITOS stock opened at $6.62 on Tuesday. iTeos Therapeutics, Inc. has a 12 month low of $4.80 and a 12 month high of $18.75. The firm has a market cap of $252.84 million, a price-to-earnings ratio of -2.10 and a beta of 1.43. The stock has a 50-day moving average price of $6.59 and a 200 day moving average price of $7.65.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.13. Sell-side analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.